RecruitingNCT05556642
Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative
Studying Hepatoblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Principal Investigator
- Katherine Somers, MD, M.DChildren's Hospital Medical Center, Cincinnati
- Intervention
- Biospecimen collection(other)
- Enrollment
- 500 enrolled
- Eligibility
- All sexes
- Timeline
- 2022 – 2040
Study locations (1)
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05556642 on ClinicalTrials.govOther trials for Hepatoblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07188311Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in ChildrenSun Yat-sen University
- RECRUITINGPHASE1, PHASE2NCT04634357ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular CarcinomaEureka Therapeutics Inc.
- RECRUITINGPHASE2NCT07300449A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and AdolescentsSun Yat-sen University
- RECRUITINGPHASE1, PHASE2NCT04901702Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing SarcomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE3NCT04478292A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT StrategyShanghai Children's Medical Center
- ACTIVE NOT RECRUITINGPHASE3NCT03017326Paediatric Hepatic International Tumour TrialUniversity of Birmingham
- ACTIVE NOT RECRUITINGPHASE3NCT00980460Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver CancerNational Cancer Institute (NCI)